1. Home
  2. GERN vs HOV Comparison

GERN vs HOV Comparison

Compare GERN & HOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.29

Market Cap

911.0M

Sector

Health Care

ML Signal

HOLD

Logo Hovnanian Enterprises Inc.

HOV

Hovnanian Enterprises Inc.

HOLD

Current Price

$123.90

Market Cap

778.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
HOV
Founded
1990
1959
Country
United States
United States
Employees
258
1891
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
911.0M
778.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GERN
HOV
Price
$1.29
$123.90
Analyst Decision
Hold
Sell
Analyst Count
3
2
Target Price
$2.17
$97.00
AVG Volume (30 Days)
8.1M
108.8K
Earning Date
05-06-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$26.91
N/A
Revenue Next Year
$43.75
$5.96
P/E Ratio
N/A
$17.50
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$91.52
52 Week High
$2.01
$162.06

Technical Indicators

Market Signals
Indicator
GERN
HOV
Relative Strength Index (RSI) 41.90 46.28
Support Level $1.24 $119.60
Resistance Level $1.46 $127.22
Average True Range (ATR) 0.07 5.70
MACD -0.02 -0.79
Stochastic Oscillator 6.52 18.57

Price Performance

Historical Comparison
GERN
HOV

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About HOV Hovnanian Enterprises Inc.

Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.

Share on Social Networks: